Arpeggio Biosciences Raises $17 Million In Series A Funding Led By Builders Vc
09/07/22, 12:08 PM
Location
boulderMoney raised
$17 million
Industry
information technology
Round Type
series a
Arpeggio Biosciences, a preclinical therapeutics company whose technology targets transcriptional dysregulation in disease, and Builders VC, today announced a $17 million dollar Series A funding round, following a $3.2 million dollar seed round completed in 2020. Funding was led by Builders VC and will support ongoing development of Arpeggio’s drug pipeline as well as its transcription-monitoring technologies.
Company Info
Location
4888 pearl east circle
boulder, colorado, united states
Additional Info
Arpeggio Biosciences is revolutionizing drug discovery by combining a proprietary biological assay with machine learning algorithms to generate rapid, high-resolution snapshots of cellular dynamics following drug treatment. These snapshots uncover the biological networks that drive a drug’s function, guiding more effective therapeutic development. Backed by a talented and diverse team, Arpeggio is dedicated to accelerating new treatments for patients with epigenetically-driven diseases.